MINNEAPOLIS, Sept. 4, 2025 /PRNewswire/ — VentureMed Group, Inc., a privately held leader in medical device innovations for arteriovenous (AV) access and peripheral arterial disease (PAD), was recently featured in a published study on the outcomes of FLEX VP + DCB in the Journal of Vascular Access, and in a recorded video conversation between Dr. Ari Kramer and Dr. Robert Shahverdyan reflecting on their experiences utilizing the FLEX VP system released by Vascular News. Additionally, a spotlight on the FLEX VP impact on operating room staff efficiency was featured in Endovascular Today.
Journal of Vascular Access: “Vessel preparation with FLEX Vessel Prep device prior to paclitaxel-coated angioplasty improves outcomes of hemodialysis vascular access”
Primary Investigator
Robert Shahverdyan, MD
Vascular Access Medicine
Hamburg, Germany
This retrospective analysis compares the efficacy of three endovascular treatment modalities in the treatment of vascular access stenoses: 1) plain-balloon angioplasty + drug coated balloon angioplasty (DCB), 2) scoring balloon (SB) + DCB, and 3) vessel prep (FLEX) + DCB in the treatment of vascular access stenoses.
Results:
- Reinterventions per patient-year were significantly lower in the FLEX group (0.372) compared to POBA (0.695) and SB (0.917) (p<0.0001)
- In cephalic arch interventions at 12-months: 75% maintained TLPP in FLEX group vs 0% in POBA and 0% in SB groups.
This analysis reported lower reintervention rates with FLEX + DCB compared to POBA or SB. The authors suggest FLEX may be a promising alternative for managing vascular access stenoses in real-world clinical settings.
FLEXing across the Pond: A candid conversation between two vascular access physician experts comparing their real-world experiences with FLEX VP in AV Access interventions
An engaging conversation between Dr. Robert Shahverdyan of Hamburg, Germany and Dr. Ari Kramer of Spartanburg, South Carolina highlighted their personal experiences incorporating FLEX VP in AV access interventions. The discussion, recorded at Charing Cross, captured insights from complex cases in their respective practices. Both physicians noted that FLEX VP offers a different approach to vessel preparation and described its use as supporting precise lesion modification prior to adjunctive therapies.
Endovascular Today: “When Vessel Prep Sets the Rhythm”
Dr. Ari Kramer’s Vascular Access Program, which performs more than 1500 AV access procedures annually, was featured for its perspective on integrating FLEX VP into their workflow. According to Dr. Kramer, his team has observed improvements in staff workflow and fewer reinterventions with regular use of FLEX VP. He commented, “We’ve come to see vessel prep as a form of therapy in its own right,” Dr. Kramer says, “FLEX VP provides consistent patient outcomes which supports more predictable and efficient care for a busy OR performing AV access procedures.”
“As more physicians incorporate FLEX VP into their practice, they report lower reintervention rates and workflow improvements,” said Denis Harrington, President & CEO of VentureMed Group. “We are encouraged by these findings and remain committed to our mission of providing products that improve the lives of patients and provide value-based solutions for providers in AV access care.”
About VentureMed Group & FLEX Vessel Prep™ System
VentureMed Group, Inc. is a pioneering medical device company dedicated to advancing endovascular solutions for arteriovenous (AV) access and peripheral arterial disease (PAD) interventions. The company’s flagship technology, the FLEX Vessel Prep™ System, is designed to optimize vessel preparation using its proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology. Unlike traditional balloon-based approaches that apply static pressure, KEMIC leverages-controlled motion and dynamic vessel apposition to create long, precise micro-incisions. As FLEX VP is pulled back through the vessel, the outward pressure of the struts ensures continuous contact with the vessel wall, while the pull-back motion of the blades generates a series of precise micro-incisions.
This unique mechanism facilitates luminal gain, may enhance drug uptake when used in combination therapy, and may reduce vessel trauma—ultimately lowering the risk of restenosis. FDA 510(k) cleared, and CE Mark approved, FLEX is redefining vessel preparation and advancing treatment options for patients worldwide.
For more information, visit www.VentureMedgroup.com.
Media contact: Tom Michals
[email protected]
+1(763) 951-0280
SOURCE VentureMed Group
